Gene Editing Therapies

“Three Months Ended March 31, $ Change % Change 2026 2025 Research and development expenses $ 150,150 $ 41,391 $ 108,759 262.8 % The increase in research and development expenses during the three months ended March 31, 2026 as compared to the same period in 2025 was primarily due to increased expenses related to clinical studies of $103.2 million, manufacturing for our drug candidates of $1.8 million, consultants of $1.7 million, salaries and benefits of $1.5 million and pre-clinical studies of $1.0 million, partially offset by a decrease in expenses related to stock-based compensation of $0.7 million.”

VKTX 10-Q · 2026-04-30

“During the three months ended March 31, 2025, cash used in operating activities of $52.3 million primarily reflected our net losses for the period, adjusted by non-cash charges such as stock-based compensation, amortization of investment premiums, amortization of right-of-use assets, amortization of financing costs, and interest expense related to operating lease liabilities as well as changes in our working capital accounts, primarily consisting of a decrease in prepaid expenses and other current assets, accrued expenses, accounts payable and lease liability, partially offset by an increase in accrued interest, net of interest received on maturity of investments.”

VKTX 10-Q · 2026-04-30

“In addition, government funding of other agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.”

VKTX 10-K · 2026-02-11